Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Rubius Therapeutics stock

Own Rubius Therapeutics stock in just a few minutes.


Fact checked

Rubius Therapeutics, Inc is a biotechnology business based in the US. Rubius Therapeutics shares (RUBY) are listed on the NASDAQ and all prices are listed in US Dollars. Rubius Therapeutics employs 197 staff and has a market cap (total outstanding shares value) of USD$917.7 million.

How to buy shares in Rubius Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Rubius Therapeutics. Find the stock by name or ticker symbol: RUBY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Rubius Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Rubius Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Rubius Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Rubius Therapeutics share price

Use our graph to track the performance of RUBY stocks over time.

Rubius Therapeutics shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$3.35 - USD$15.1
50-day moving average USD$11.1862
200-day moving average USD$6.9927
Wall St. target priceUSD$11.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.696

Buy Rubius Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rubius Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rubius Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -28.9%
Return on equity TTM -71.46%
Profit margin 0%
Book value $2.139
Market capitalisation USD$917.7 million

TTM: trailing 12 months

Shorting Rubius Therapeutics shares

There are currently 7.6 million Rubius Therapeutics shares held short by investors – that's known as Rubius Therapeutics's "short interest". This figure is 4.7% down from 8.0 million last month.

There are a few different ways that this level of interest in shorting Rubius Therapeutics shares can be evaluated.

Rubius Therapeutics's "short interest ratio" (SIR)

Rubius Therapeutics's "short interest ratio" (SIR) is the quantity of Rubius Therapeutics shares currently shorted divided by the average quantity of Rubius Therapeutics shares traded daily (recently around 580962.16628528). Rubius Therapeutics's SIR currently stands at 13.11. In other words for every 100,000 Rubius Therapeutics shares traded daily on the market, roughly 13110 shares are currently held short.

However Rubius Therapeutics's short interest can also be evaluated against the total number of Rubius Therapeutics shares, or, against the total number of tradable Rubius Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rubius Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Rubius Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.2839% of the tradable shares (for every 100,000 tradable Rubius Therapeutics shares, roughly 284 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rubius Therapeutics.

Find out more about how you can short Rubius Therapeutics stock.

Rubius Therapeutics share dividends

We're not expecting Rubius Therapeutics to pay a dividend over the next 12 months.

Rubius Therapeutics share price volatility

Over the last 12 months, Rubius Therapeutics's shares have ranged in value from as little as $3.35 up to $15.1. A popular way to gauge a stock's volatility is its "beta".

RUBY.US volatility(beta: 2.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rubius Therapeutics's is 2.2235. This would suggest that Rubius Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Rubius Therapeutics overview

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site